WRSs2 Shigella Vaccine Shows 89% Efficacy in Phase 2 Trial

A Phase 2 controlled human infection trial published on September 1, 2026, in The Lancet Infectious Diseases has shown substantial progress in the development of a vaccine against Shigella sonnei. The WRSs2 vaccine, a live-attenuated oral treatment, provided 89% protection among participants. This result marks the highest efficacy reported for any Shigella vaccine candidate to date. The trial included 73 participants who completed the challenge phase without any serious adverse events.

The research is part of a long-term effort to combat Shigella, a diarrheal pathogen known for its global health impact and resistance to antibiotics. This development follows more than a century of work to create a safe vaccine against the infection. Historically, Shigella has posed a major challenge in both developed and developing countries, where it causes severe gastrointestinal disease. These successful trial results represent a pivotal step toward addressing the issue.

Researchers hope to eventually offer a licensed vaccine that can prevent infections, particularly in high-risk groups. The Phase 2 findings pave the way for larger studies to confirm the vaccine's efficacy in more diverse populations. These upcoming trials will continue to evaluate safety and effectiveness across different demographics, ensuring the vaccine can be used widely to protect vulnerable people from the disease.

The success of the WRSs2 vaccine could have broader significance in the effort to manage antibiotic-resistant pathogens. As resistance rises, the development of effective vaccines becomes increasingly important. This advancement is a breakthrough for Shigella research and may serve as a model for future vaccines against other resistant bacteria, potentially changing public health strategies on a global scale.